GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function
Completed
- Conditions
- Neoplasms
- Interventions
- Other: Qualitative InterviewsOther: PROMIS Physical Function Items
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT03351140
- Locations
- 🇺🇸
GSK Investigational Site, Mountlake Terrace, Washington, United States
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo ELLIPTADrug: Standard of care therapy
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 943
- Registration Number
- NCT03345407
- Locations
- 🇬🇧
GSK Investigational Site, Stockton-on-Tees, United Kingdom
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Completed
- Conditions
- Asthma
- Interventions
- Other: Telephonic interviewsOther: Supplemental asthma itemsOther: Daily diaryOther: Sociodemographic questionnaireOther: Clinical questionnaire
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT03344406
- Locations
- 🇺🇸
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives in Denture Wearers
Not Applicable
Completed
- Conditions
- Denture Retention
- Interventions
- Device: Denture Adhesive Cream (Conventional Application)Device: Denture Adhesive (Continuous Strip Application)Other: No Adhesive
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT03345108
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer
Completed
- Conditions
- Neoplasms
- Interventions
- Other: Telephonic interview
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT03336567
- Locations
- 🇺🇸
GSK Investigational Site, Collegeville, Pennsylvania, United States
Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Anxiety Disorders
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 85
- Registration Number
- NCT03329573
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions
Phase 1
Withdrawn
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03329547
Pediatric Ease of Use ELLIPTA Items
Completed
- Conditions
- Asthma
- Interventions
- Other: Interviewer administered version of ease of use itemsOther: Self-administered version of ease of use itemsOther: Caregiver version of ease of use items
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT03315572
- Locations
- 🇺🇸
GSK Investigational Site, Raleigh, North Carolina, United States
Absorption & Elimination of Radiolabelled GSK2269557
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: [14C]-GSK2269557 IV infusionDrug: GSK2269557 via DPIDrug: [14C]-GSK2269557 oral solution
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03315559
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
Phase 3
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Rituximab-placeboDrug: Standard therapy (Including Immunosuppressants)Drug: Standard therapy (Excluding Immunosuppressants)Drug: Steroid Taper
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT03312907
- Locations
- 🇪🇸
GSK Investigational Site, Vigo (Pontevedra), Spain
© Copyright 2025. All Rights Reserved by MedPath